✦ LIBER ✦

A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer

✍ Scribed by Y.-K. Kang; B.-Y. Ryoo; T. Y. Kim; Y.-H. Im; B.-S. Kim; Y.-H. Park; C.-T. Lee

Publisher: Springer
Year: 1999
Tongue: English
Weight: 72 KB
Volume: 44
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800051127

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of edatrexate in small ce

Phase II trial of edatrexate in small cell lung cancer

✍ Martin Wiesenfeld; James R. Jett; John Q. Su; Theodore A. Braich; Carl G. Kardin 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 2 views

Carboplatin and vinblastine in advanced

Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study

✍ D. Doll; M. Goutsou; S. Graziano; J. Ellerton; J. Bitran; C. Modeas; J. Herndon; 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 426 KB

Phase II trial of piroxantrone in advanc

Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung

✍ Stephen K. Williamson; John J. Crowley; Robert Livingston; Alexander Hantel; Jam 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 144 KB

Front-line paclitaxel and topotecan chem

Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial

✍ G. P. Stathopoulos; C. Katis; D. Tsavdaridis; J. Dimitroulis; D. Karaindros; J. 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 217 KB

Phase II trial of VP16-213 in non-small

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

✍ Robert Chapman; Loretta Itri; Richard Gralla; David Kelsen; Ephraim Casper; Robe 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 238 KB

A phase II trial of oral 4′ demethoxydau

A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

✍ P. Presgrave; R. Woods; R. Kefford; D. Bell; D. Raghavan; J. Levi 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 216 KB

4' Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m 2 and 40 mg/m 2 respectively at 28 day intervals. All 22 pat